Enesi Pharma Adds to Scientific Advisory Board

Enesi Pharma has announced the appointment of Dr. Steven Chatfield to its Scientific Advisory Board (SAB).

Dr. Chatfield is a vaccine and infectious disease expert and brings nearly 40 years' experience in R&D, executive, board and advisory roles across a number of public and private healthcare organizations focused on this area. He has a track record of success through all stages of product discovery and development leading to registration, and has provided expert advice to industry, government and non-governmental organizations on vaccines, vaccination and public health issues, including biodefence.

Dr. Chatfield is currently a Non-executive Director of the Vaccines Manufacturing & Innovation Centre (VMIC), a new purpose-built, state-of-the-art facility in Oxford, UK, allowing for academic and industry collaboration on the development, design and manufacture of vaccines. He is also a Director of the UK Cell and Gene Therapy Catapult and a member of the Scientific Advisory Board of the Jenner Institute at the University of Oxford, one of the oldest and most renowned vaccine research centers in the world. Dr. Chatfield is Chairman of Prokarium, a UK company developing oral vaccine products for infectious diseases and cancer.

Previously, Dr. Chatfield served as Chief Scientific Officer and Executive Vice President of Strategic Investments for Emergent BioSolutions, a global vaccine business, and was President and CEO of its UK operation. He was also a Director of Vaccitech, a private UK vaccine specialist, and a Director of the Centre for Emergency Preparedness and Response at the UK Health Protection Agency (now Public Health England).

Dr. Chatfield has published over 100 publications on the molecular basis of pathogenicity of bacterial and viral infections and work directed towards the development of novel vaccines and immunotherapeutics, being a named inventor on 20 patents.

"We are very proud at Enesi to have been able to attract highly experienced and distinguished vaccine and vaccination experts to our SAB," David Hipkiss, CEO of Enesi Pharma, said. "The SAB provides importance guidance on key issues within the sector and where our ImplaVax® platform could make the greatest impact. This has enabled us to prioritise and execute our strategic activities with considerable success to date in terms of the quality of our collaborations and our profile within the industry. Dr Chatfield is a fantastic addition, bringing unique and highly complementary experience and expertise to our SAB. We look forward to his contribution to our growing business."

-----------------------------------------------------------------------
Editor's Note:

If you have any suggestion to the content, 

please email: Julia.Zhang@ubmsinoexpo.com